組織蛋白酶L(CTSL)重組蛋白
Recombinant Cathepsin L (CTSL)
CTSL1; CATL; CTS-L; MEP; Cathepsin L1; Major excreted protein
- 編號(hào)RPA306Fi01
 - 物種Danio rerio (Zebrafish,斑馬魚(yú))相同的名稱,不同的物種。
 - 來(lái)源原核表達(dá)
 - 宿主E.coli
 - 內(nèi)毒素水平<1.0EU/µg(LAL法測(cè)定)
 - 亞細(xì)胞定位n/a
 - 預(yù)測(cè)分子量-
 - 實(shí)際分子量-(差異分析請(qǐng)參閱說(shuō)明書(shū))
 - 片段與標(biāo)簽N-terminal His Tag
 - 緩沖液成份磷酸鹽緩沖液(pH7.4,含有 0.01% SKL, 1mM DTT, 5% Trehalose和Proclin300.)
 - 性狀凍干粉
 - 純度> 97%
 - 等電點(diǎn)-
 - 應(yīng)用Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白,請(qǐng)參見(jiàn)活性蛋白。 - 下載英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
 - 規(guī)格10μg50μg200μg1mg5mg
 - 價(jià)格¥ 984¥ 2460¥ 4920¥ 14760¥ 36900
 - 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
 
序列
用法
PBS或其它。
儲(chǔ)存
避免反復(fù)凍融。2-8°C不超過(guò)一個(gè)月,-80°C不超過(guò)12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定,具體方法如下:在37°C孵育48小時(shí),沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲(chǔ),損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種:Danio rerio (Zebrafish,斑馬魚(yú)) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) | 
| RPA306Fi01 | 組織蛋白酶L(CTSL)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. | 
| PAA306Fi01 | 組織蛋白酶L(CTSL)多克隆抗體 | WB; IHC; ICC; IP. | 
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) | 
| Hypertension | Identification of Cathepsin L as a Potential Sex-Specific Biomarker for Renal Damage. [Ahajournals: source] | 
| The Journal of International Medical Research | Plasma Cathepsin L and Its Related Pro/Antiangiogenic Factors Play Useful Roles in Predicting Rich Coronary Collaterals in Patients with Coronary Heart Disease[Ingenta: art00021] | 
| Atherosclerosis.? | Biochemical and clinical correlation of intraplaque neovascularization using contrast-enhanced ultrasound of the carotid artery[Pubmed:24534452] | 
| International Journal of Molecular Sciences | A New Analytical Method for Determination of Cathepsin L Based on the Surface Plasmon Resonance Imaging Biosensor[Pubmed: 31052424] | 
| EMBO Molecular Medicine | Immune‐mediated ECM depletion improves tumour perfusion and payload delivery[Pubmed: 31709774] | 
| Cardiovasc Res | Inhibition of myocardial cathepsin-L release during reperfusion following myocardial infarction improves cardiac function and reduces infarct size[34132807] | 


